Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 5:11:784.
doi: 10.3389/fphar.2020.00784. eCollection 2020.

Surveillance of the Efficacy of Artemisinin-Piperaquine in the Treatment of Uncomplicated Plasmodium falciparum Malaria Among Children Under 5 Years of Age in Est-Mono District, Togo, in 2017

Qi Wang  1 , Zhenyan Zhang  1 , Weisheng Yu  1 , Chenguang Lu  1 , Guoming Li  1 , Ziyi Pan  1 , Hongying Zhang  1 , Wanting Wu  1 , Tinah Atcha Oubou  2 , Yueming Yuan  1   3 , Jiawen Guo  1   3 , Yuan Liang  1 , Xinan Huang  1 , Wenfeng Guo  1 , Changqing Li  1 , Nadia Julie  1 , Qin Xu  1 , Logte Sanwogou  4 , Jianping Song  1 , Changsheng Deng  1
Affiliations

Surveillance of the Efficacy of Artemisinin-Piperaquine in the Treatment of Uncomplicated Plasmodium falciparum Malaria Among Children Under 5 Years of Age in Est-Mono District, Togo, in 2017

Qi Wang et al. Front Pharmacol. .

Abstract

Background: Malaria is a major public health concern in Togo. The Est-Mono district of Togo has a population of 150,000. Accordingly, the Guangzhou University of Chinese Medicine, China and the Ministry of Health and Social Security, Togo launched a nationwide Mass Drug Administration Project with artemisinin-piperaquine (AP) in Est-Mono. Before launching this project, the sensitivity test of AP was conducted in a general clinic in Elawagnon, Togo. With this background, we evaluated the efficacy and safety of AP for the treatment of uncomplicated falciparum malaria in children under the age of 5 years.

Methods: Children aged 6-59 months with uncomplicated falciparum malaria were enrolled in this study. The selected patients were treated with a combination regime of artemisinin-piperaquine. The patients were followed up for 28 days, during which signs of the following were observed for: the duration for fever clearance, parasitemia density, gametophyte generation, cure rate, hemoglobin level, and merozoite surface protein-2 (msp-2) polymorphism. The primary end point was a 28-day cure rate and polymerase chain reaction (PCR)-corrected reinfection and recrudescence. This research followed the standardized World Health Organization (WHO) protocol for the assessment of the efficacy of antimalarial drugs.

Results: A total of 91 children with uncomplicated falciparum malaria were enrolled in this study. Adequate clinical and parasitological responses (ACPRs) before and after PCR-correction were 66 (73%) and 90 (99%), respectively. The average hemoglobin level in the patient increased by 0.05 g/dl per day (p < 0.0001) after the treatment. The gametophyte generation did not decline at the beginning of the treatment; however, after 14 days, it declined (day 21: p < 0.05; day 28: p < 0.01). In the msp-2 polymorphism study of 24 children treated for parasite infection, one case of msp-2 with 3D7 haplotype and FC27 haplotype was noted, indicating its recrudescence, with a frequency of 4%. The remaining 23 cases could have been of reinfection, with a frequency of 96%. No serious adverse reactions occurred, and AP was well-tolerated by all patients.

Conclusion: Artemisinin-piperaquine was found to be an effective combination for treating uncomplicated falciparum malaria in children aged <5 years in Togo, and the drugs were well-tolerated. In Togo, Plasmodium falciparum remains sensitive to artemisinin-piperaquine, necessitating its trial in this region.

Clinical trial registration: Trial registration: ECGPHCM No. B2017-054-01; MHSST AVIS N° 0001/2016/CBRS du 07 janvier 2016. Registered 17 March 2014, http://www.chinadrugtrials.org.cn/eap/main.

Keywords: Plasmodium falciparum; Togo; artemisinin–piperaquine; gametophyte; merozoite surface protein-2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow chart in the clinical trial. ACPR, adequate clinical and parasitological response; ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; TF, treatment failure; P.f, Plasmodium falciparum; P.m, Plasmodium malariae; P.o, Plasmodium ovale.
Figure 2
Figure 2
Body temperature and parasitemia across days after treatment. Y axis represents the temperature (A) and parasitemia (B) in patients. The significance levels are shown as significant (****: p < 0.0001) and nonsignificant (NS). All data were analyzed with one-way ANOVA and multiple comparisons. Error bars show the standard error of the mean (SEM).
Figure 3
Figure 3
Gametocytemia (A), mean gametocytemia (B), and hemoglobin level (C) of patients from day 0 to day 28. The significance levels are shown as significant (****: p < 0.0001; **: p < 0. 01; *: p < 0. 05) and nonsignificant (NS). The gametocytemia and hemoglobin level of different groups were analyzed with one-way ANOVA and multiple comparisons. Error bars show the standard error of the mean (SEM).
Figure 4
Figure 4
White blood cells (A), parasitemia (B), and gametocytemia (C) of 24 patients with positive parasite detection after treatment on D0 and D28. The significance levels are shown as: significant (***: p < 0. 001; **: p < 0. 01; *: p < 0. 05) and nonsignificant (NS). White blood cells and parasitemia of 24 patients were analyzed with one-way ANOVA, and gametocytemia was analyzed with one-way ANOVA and multiple comparisons. Error bars show the standard error of the mean (SEM).
See this image and copyright information in PMC

References

    1. Adithya C., Daniel K., Alan H., Philip J. R., Grant D. (2003). Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am. J. Trop. Med. Hyg. 68 (2), 33–139. 10.1016/S0001-706X(02)00236-X - DOI - PubMed
    1. Améyo M. D., Degninou Y., Yao M. A., Yao L., Foli A., Poukpessi A., et al. (2016). Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo 2012-2013. Malaria J. 15 (331). 10.1186/s12936-016-1381-8 - DOI - PMC - PubMed
    1. Assimadi J. K., Gbadoe A. D., Atakouma D. Y., Agbenowossi K., Evi L. K., Gayibor A., et al. (1998). Severe malaria in Togolese children. Arch. Pediatr. 5 (12), 1310–1315. 10.1016/S0929-693X(99)80048-7 - DOI - PubMed
    1. Aubouy A., Migot-Nabias F., Deloron P. (2003). Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malaria J. 9, 2–12. 10.1186/1475-2875-9-S2-O2 - DOI - PMC - PubMed
    1. Aurore O. H., Christian A., Souliatou L., Georgia D., Yolande S., Franck R., et al. (2016). Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin. Malaria J. 15 (37). 10.1186/s12936-016-1091-2 - DOI - PMC - PubMed